About 1 in 4 people taking antipsychotic medications will develop tardive dyskinesia (TD) at some point during treatment. The global mean prevalence sits at roughly 25.3%, though individual risk varies widely depending on the type of medication, how long you take it, your age, and your sex. In the United States alone, at least 500,000 people are currently living with the condition.
Overall Prevalence Among Antipsychotic Users
Estimates for TD prevalence among people on antipsychotics range from 20% to 50%, with a commonly cited global average of 25.3%. That wide range reflects real differences in study populations, medication types, and how carefully clinicians screen for the condition. Reported incidence (the rate of new cases) ranges from less than 1% to as high as 42% per year, depending on the drug being studied and the age of the patients.
These numbers almost certainly undercount the true burden. Antipsychotics can actually mask TD symptoms while you’re taking them, making the involuntary movements less visible until a dose is reduced or stopped. Many patients aren’t aware of their own symptoms, and clinicians don’t always document mild cases. So the real prevalence may be higher than what clinical records suggest.
Older vs. Newer Antipsychotics
The type of antipsychotic you take makes a meaningful difference. Older antipsychotics (first-generation drugs like haloperidol) carry roughly double the annual risk compared to newer ones (second-generation drugs like risperidone or quetiapine). In randomized controlled trials, the annualized incidence of TD was 6.5% per year for first-generation antipsychotics versus 2.6% per year for second-generation antipsychotics.
That difference is significant, but it’s important to note that second-generation antipsychotics are not risk-free. A 2.6% annual rate means that over several years of continuous use, a substantial number of people on newer medications will still develop TD. The newer drugs reduced the risk; they didn’t eliminate it.
How Risk Increases Over Time
TD is rare when antipsychotic exposure lasts less than three months. The risk climbs meaningfully after one to two years of near-continuous use, and it continues to accumulate the longer treatment continues. Both the total duration of treatment and the cumulative dose contribute to risk.
For younger adults with schizophrenia, the estimated incidence is about 4% to 5% per year. That means after five years of treatment, roughly 20% to 25% of younger patients may have developed TD. For adults over 50, meta-analyses project an annual rate closer to 5%, though older patients with no prior antipsychotic exposure face dramatically steeper odds (more on that below).
Age Is the Strongest Risk Factor
Older adults are far more vulnerable to TD than younger people. In studies of patients older than 45 with little or no previous antipsychotic exposure, the one-year cumulative incidence reached 25% to 26%. That’s roughly five to six times the annual rate seen in younger adults. A separate study of patients aged 55 and older found a similar one-year rate of 25%.
For adults over 60, TD can appear even faster. Current guidelines note that TD risk becomes relevant after just one month of antipsychotic use in this age group, compared to three months for younger adults. This accelerated timeline is one reason screening recommendations are more frequent for older patients.
Women Are Affected More Often
Across a large body of research covering nearly 40,000 patients, the overall TD prevalence was 26.6% in women compared to 21.6% in men. Women also tend to develop more severe forms of TD. The reasons aren’t fully understood, but hormonal differences, body composition affecting drug metabolism, and potentially higher relative doses in women of smaller body size have all been proposed as contributing factors.
Non-Psychiatric Medications Carry Risk Too
TD isn’t limited to people taking antipsychotics for psychiatric conditions. Metoclopramide, a drug commonly prescribed for nausea and gastroparesis, also causes TD. The FDA warns that risk increases with longer treatment duration and higher cumulative doses, and recommends against using the drug for more than 12 weeks except in rare cases. Older adults, women, and people with diabetes face elevated risk from metoclopramide specifically, though it’s not possible to predict exactly who will be affected.
How Screening Works
Because TD often develops gradually and can go unnoticed by both patients and clinicians, professional guidelines recommend regular screening using a standardized assessment called the Abnormal Involuntary Movement Scale (AIMS). This is a brief physical exam where a clinician watches for involuntary movements in your face, tongue, jaw, trunk, and limbs.
The American Psychiatric Association recommends AIMS screening every 6 months for people taking first-generation antipsychotics and every 12 months for those on second-generation drugs. If you have additional risk factors, like older age or female sex, the recommended frequency doubles: every 3 months for first-generation antipsychotics and every 6 months for second-generation ones. Despite these guidelines, screening in routine clinical practice is inconsistent, which contributes to underdiagnosis.
Why Many Cases Go Unrecognized
TD is likely more common than clinical records show. Several factors drive underdiagnosis. The antipsychotic medications that cause TD can simultaneously suppress its visible symptoms, so the movements may only become obvious when a dose is changed. Many patients don’t recognize their own involuntary movements, particularly mild ones affecting the tongue or lower face. And some clinicians, especially those outside psychiatry, may not be familiar enough with TD to catch subtle cases during routine visits.
This gap between actual prevalence and documented prevalence means that if you’re taking an antipsychotic or metoclopramide, proactive screening matters. Catching TD early gives you more options, since the condition is easier to manage when identified before it becomes severe or entrenched.